Latest EHE News, Events & Research

EHE Foundation Awards $335,000 in New Research Grants to Advance Progress in EHE

March 16, 2026

The EHE Foundation is proud to announce $335,000 in funding through the 2026 EHE Foundation Research Grants Program to support two innovative research projects in epithelioid hemangioendothelioma (EHE). Selected for their scientific merit, potential impact, and clinical relevance, these projects address two important priorities in EHE research: biomarker development and new therapeutic approaches. Together, they […]

BreAnn W.

March 16, 2026

BreAnn’s Story: “Keep Fighting. Find Your Path, and Just Live.” BreAnn’s journey with epithelioid hemangioendothelioma (EHE) began with a moment that seemed almost ordinary at first — lifting her 1-year-old daughter out of her crib. “It all started with a broken back after lifting my then 1-year-old out of her crib,” BreAnn said. “I felt […]

Ashley W.

March 11, 2026

Ashley’s Story: “Today Matters.” When Ashley discovered a mass in her own liver, her life changed in an instant. As a diagnostic medical sonographer, she was used to helping others navigate medical uncertainty. She never expected to face it herself. “I am a diagnostic medical sonographer, and I found a mass in my own liver,” […]

The Pledge: Edition 43, Q4 – October-December, 2025

February 15, 2026

Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe provide content, including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of the online EHE newsletter, The Pledge.

Understanding Quality of Life for People Living With EHE

February 10, 2026

The European Organisation of Research and Treatment of Cancer (EORTC) is conducting research to better understand health-related quality of life (HRQoL) concerns among people living with rare cancers. Recently, researchers analyzed results from a group of 31 people with EHE from 11 different countries who participated in the study. The findings showed that pain–and the […]

Exploring Eribulin as a Potential Treatment Option for EHE

February 10, 2026

Prior research has shown that a class of medications called microtubule inhibitors may be effective at controlling the growth of EHE tumors. Recently, researchers conducted a phase 2 study to test whether the microtubule inhibitor eribulin is a safe and effective way to treat patients whose tumors continued to grow after prior treatment. Six (6) […]

EHE Foundation Welcomes Two Leading Sarcoma Experts to Its Scientific & Medical Advisory Board

February 8, 2026

EHE Foundation is pleased to announce the appointment of two distinguished physician-scientists to its Scientific & Medical Advisory Board: Nam Quoc Bui, MD, and Benjamin A. Nacev, MD, PhD. Their expertise in sarcoma medical oncology and translational research will greatly strengthen the Foundation’s advisory capacity as we work to accelerate progress in understanding and treating […]

Reflecting on 2025 and Looking Ahead With Purpose

January 20, 2026

For the global EHE community, 2025 brought challenges, resilience, and momentum. Grounded in connection and a shared commitment to progress in EHE, we look back with emotion, appreciation, and gratitude, and in 2026, we look forward with determination and hope.

Translating molecular mechanisms of EHE to improve patient outcomes

December 17, 2025

Scientists know that most EHE tumors are caused by specific genetic changes called gene fusions. In most people with EHE, two genes, WWTR1 and CAMTA1, are abnormally fused. In a smaller number of cases, a different fusion involving YAP1 and TFE3 is present. In a recent review published in Critical Reviews in Oncology/Hematology, the authors […]

EHE in Canada: what a national study tells us

December 17, 2025

A recent study published in the European Journal of Cancer represents the largest collection of data from people with EHE in Canada. Researchers found that EHE can behave very differently from person to person—about one-third of patients were diagnosed by chance and did not need immediate treatment, while others had more aggressive disease. About half […]